Bone metastases in lung carcinoids: current challenges in diagnosis and treatment -A systematic review of an unexplored issue.
EndocrineSep 9, 2026 (epub)
Alice Laffi, Andrea Gerardo Antonio Lania, Anna Arecco et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined bone metastases (BMs) in lung carcinoid patients, revealing an incidence of 17.2%. The study highlighted the challenges in diagnosis and treatment, noting that BMs were predominantly osteoblastic and symptomatic at diagnosis. The median survival rate was 48.32 months, with 24.9 months from detection of BMs.
Key findings
- The incidence of bone metastases in lung carcinoid patients was found to be 17.2%.
- Osteoblastic bone metastases were predominant, with vertebrae being the most common site.
- Bone scintigraphy was positive in all cases assessed.
- Median survival was 48.32 months, with 24.9 months from the detection of bone metastases.
Why it matters
Understanding the incidence and characteristics of bone metastases in lung carcinoids is crucial for improving diagnosis and treatment strategies, as these patients face significant challenges and poorer prognoses compared to those without metastases.